Commentary

Podcast

Pharmacy Focus: Policy Edition - PBM Audits

Tune into this episode as Dae Lee, PharmD, Esq, CPBS , and Harini Bupathi, Esq, attorneys at Frier Levitt, engage in a thought-provoking conversation on the evolving landscape of pharmacy benefit manager (PBM) audit strategies, regulations, and enforcement.

On this episode, Dae Lee, Pharm.D., Esq., CPBS , and Harini Bupathi, Esq, attorneys at Frier Levitt, engage in a thought-provoking conversation on the evolving landscape of pharmacy benefit manager (PBM) audit strategies, regulations, and enforcement. The discussion covers notable trends in PBM audit strategies, challenges and opportunities for pharmacies in 2024.

Key Takeaways

  1. PBM audit strategies are continually evolving, and pharmacies should stay vigilant in adapting to emerging trends.
  2. The challenges and opportunities for pharmacies in 2024 are intricately linked to the dynamic regulatory landscape surrounding PBMs.
  3. Proactive measures, robust compliance programs, and thorough documentation are essential components for pharmacies to minimize risks and disruptions.
  4. Pharmacies should be mindful of common pitfalls when engaging with regulatory bodies post-PBM audit.

Listen on Apple Podcasts and Spotify.

Related Videos
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC